CE vs ZYME · rev $10.28B vs rev $76.3M
Celanese Corporation (CE) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Celanese Corporation (CE) is a chemicals company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
CE currently screens at market cap $5.92B. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the CE and ZYME stock pages for the full models.
Not investment advice.